According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, Cantor Fitzgerald reaffirmed a buy rating and set a $20.00 price target on shares of Neos Therapeutics in a research note on Wednesday, March 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $9.75.
Neos Therapeutics stock opened at $2.43 on Wednesday. The company has a market capitalization of $119.30 million, a PE ratio of -1.52 and a beta of 0.99. Neos Therapeutics has a 1 year low of $1.40 and a 1 year high of $8.70. The company has a debt-to-equity ratio of 5.51, a current ratio of 1.55 and a quick ratio of 1.37.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, March 14th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $18.90 million. On average, sell-side analysts predict that Neos Therapeutics will post -0.71 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in NEOS. Nantahala Capital Management LLC bought a new stake in shares of Neos Therapeutics in the 4th quarter valued at about $7,400,000. Stonepine Capital Management LLC increased its stake in shares of Neos Therapeutics by 1,747.2% in the fourth quarter. Stonepine Capital Management LLC now owns 4,210,153 shares of the company’s stock valued at $6,947,000 after buying an additional 3,982,234 shares during the period. BlackRock Inc. raised its position in shares of Neos Therapeutics by 28.8% during the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after acquiring an additional 610,660 shares during the last quarter. Broadfin Capital LLC bought a new position in shares of Neos Therapeutics during the fourth quarter worth about $4,321,000. Finally, Franklin Resources Inc. raised its position in shares of Neos Therapeutics by 8.4% during the third quarter. Franklin Resources Inc. now owns 2,493,239 shares of the company’s stock worth $12,092,000 after acquiring an additional 193,500 shares during the last quarter. 50.83% of the stock is currently owned by hedge funds and other institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Article: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.